APA
Holgersson G., Bergqvist M., Nilsson J., Thureson M., Harmenberg J. & Bergstrom S. (062017). The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial. : Asian Pacific journal of cancer prevention : APJCP.
Chicago
Holgersson Georg, Bergqvist Michael, Nilsson Jonas, Thureson Marcus, Harmenberg Johan and Bergstrom Stefan. 062017. The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial. : Asian Pacific journal of cancer prevention : APJCP.
Harvard
Holgersson G., Bergqvist M., Nilsson J., Thureson M., Harmenberg J. and Bergstrom S. (062017). The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial. : Asian Pacific journal of cancer prevention : APJCP.
MLA
Holgersson Georg, Bergqvist Michael, Nilsson Jonas, Thureson Marcus, Harmenberg Johan and Bergstrom Stefan. The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial. : Asian Pacific journal of cancer prevention : APJCP. 062017.